Table 2.
Determination of HF anticlastogenic effect towards cisplatin using the chromosome aberration test on HepG2 and VH10 cells.
| HF/cisPt Concentration (µM) | Number of Aberrant Metaphases | Number of Chromosome Aberrations | Total Number of CA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chromatid | Isochromatid | Exchange | |||||||||
| g | b/f | g | b/f | ring | dic | qr | tr | dmin | |||
| HepG2 | |||||||||||
| IC | 2 | 1 | 2 | 1 | - | - | - | - | - | - | 2 |
| SC | 3 | 1 | 2 | - | - | - | 1 | - | - | - | 3 |
| HF 0.75 | 1 | 1 | 1 | - | - | - | - | - | - | - | 1 |
| HF 1.5 | 3 | - | 2 | - | 1 | - | - | - | - | - | 3 |
| PC cisPt 0.5 | 38 *** | 2 | 36 | - | 8 | - | 2 | 1 | - | - | 47 *** |
| HF 0.75+ cisPt 0.5 | 10 *,### | 2 | 5 | - | 4 | - | 2 | - | - | - | 11 *,### |
| HF 1.5 + cisPt 0.5 | 14 **,### | 2 | 10 | - | 3 | - | 1 | - | - | - | 14 **,### |
| VH10 | |||||||||||
| IC | 2 | - | 2 | - | - | - | - | - | - | - | 2 |
| SC | 2 | 1 | 1 | 1 | - | - | 1 | - | - | - | 2 |
| HF 0.75 | 1 | - | 1 | - | - | - | - | - | - | - | 1 |
| HF 1.5 | 1 | - | - | - | - | - | 1 | - | - | - | 1 |
| PC cisPt 0.75 | 33 *** | 2 | 26 | - | 9 | - | - | 4 | 5 | - | 44 *** |
| HF 0.75 + cisPt 0.75 | 12 **,### | 1 | 8 | - | 3 | - | 1 | 1 | 1 | - | 14 ***,### |
| HF 1.5 + cisPt 0.75 | 11 **,### | 3 | 8 | - | - | - | 1 | - | 2 | - | 11 **,### |
IC—intact control; SC—solvent control (PBS); HF—hyperforin; PC cisPt—positive control (cisplatin); CA—chromosome aberrations; g—gap; b/f—break and/or fragment; dic—dicentric; qr—quadriradial; tr—triradial. Comparison with solvent control (SC): * 0.01 < p < 0.05; ** 0.001 < p < 0.01; *** p < 0.001. Comparison with positive control (PC): ###p < 0.001.